Inclusion Criteria for Screening (Visit 1):

          1. At least 19 years of age

          2. Patients who have been diagnosed with histologically confirmed extranodal NK/T-cell
             lymphoma (ENKTL) as per WHO classification, and who have been found to be positive for
             EBV encoded RNA (EBER) by in situ hybridization (ISH) (previous test results may be
             used as evidence if available)

          3. Patients with active diseases or in high-risk group A. Active diseases

               1. Patients who are suspected/confirmed to have relapsed/progressed after first- or
                  second-line asparaginase based regimen,

               2. Intolerant patients for whom asparaginase based regimen is not feasible or who
                  cannot complete at least one full cycle of asparaginase based regimen, OR

               3. Refractory patients who have recurrence at least 3 months after the completion of
                  first-line asparaginase based regimen B. High-risk group

               1. Korean prognostic index (KPI) 3-4, OR

               2. International prognostic index (IPI) high-intermediate

          4. Voluntarily provided a written consent to participate in Epitope screening

        Enrollment Criteria (Visit 2)

          1. Persons who have passed the epitope screening test and who have been found to be
             capable of production

          2. Patients who failed standard or conventional regimen and meet at least one of the
             following:

        A. Patients who have relapsed/progressed after first or second-line anticancer therapy B.
        Intolerant patients for whom anticancer therapy is not feasible or who cannot complete at
        least one full cycle of first-line anticancer therapy C. Refractory patients who have
        recurrence at least 3 months after the completion of first-line anticancer therapy 3) At
        least one lesion with > 15 mm long axis, or 18FDG-PET/CT-avid 4) Eastern Cooperative
        Oncology Group (ECOG) performance status of 0 to 2 5) Persons with appropriate liver,
        renal, and bone marrow function (two retests are permitted for borderline results, and
        corrections such as transfusions to meet the requirements are permitted)

          1. Absolute neutrophil count (ANC) more than 1,000/μL

          2. Absolute lymphocyte count (ALC) more than 500/μL

          3. Platelet count more than 75,000/μL

          4. Serum creatinine less than 2.0 mg/dL

          5. AST and/or ALT less than 3 x upper limit of normal range (ULN)

          6. Total bilirubin less than 2.0 mg/dL

          7. Life expectancy of at least 12 weeks

          8. Pregnant women, breast-feeding women, or women of childbearing potential who do not
             agree to use adequate contraceptive measures 8) Voluntarily provided a written consent
             to participate in the study

        Exclusion Criteria (Visit 1):

          1. Patients with aggressive NK cell leukemia

          2. Patients with hemophagocytic lymphohistiocytosis (HLH)

          3. Persons who have previously received a solid organ transplant

          4. Persons who have been diagnosed with a malignant tumor other than the target disease
             in the past 5 years (treated basal cell carcinoma, squamous epithelial cell carcinoma,
             and non-invasive cervical cancer do not necessitate exclusion)

          5. Patients in whom a tuberculosis infection was confirmed in the 1 year prior to
             screening for the present study

          6. Pregnant or lactating women

          7. HIV positive

          8. Patients deemed unsuitable to participate in the clinical trial by an investigator
             based on active infection (HBV, HCV) test results

        Exclusion Criteria (Visit 2):

          1. Where central nervous system (CNS) lymphoma or uncontrolled CNS metastasis is present
             (patients with brain metastasis that has been treated and is stable [stable for at
             least 30 days based on radiology records] may be enrolled)

          2. Persons who have received surgery, radiotherapy, or chemotherapy in the 3 weeks prior
             to administration of IP

          3. Persons who have been administered any other investigational product in the 3 weeks
             prior to administration of IP

          4. Persons who have not recovered from the toxicity of any previous treatment to Grade 1
             or lower based on NCI CTCAE v5.0

          5. Patients who have received immunosuppressants, including steroids, in the 10 days
             prior to blood collection for IP production (visit 2) (local steroids and steroid
             inhalers are permitted, and steroid equivalent to 20 mg/day of prednisolone may be
             administered at the investigator's discretion)

          6. Patients with the following (but not limited to) clinically significant cardiovascular
             comorbidities as determined by the investigator

             : Uncontrolled hypertension (i.e., systolic pressure > 180 mmHg and/or diastolic
             pressure > 100 mm/Hg), unstable angina, pulmonary embolism, cerebrovascular disease,
             valvular disease, congestive heart failure (NYHA severity classification Grade III or
             IV), or myocardial infarction or serious cardiac arrhythmia within the 24 weeks prior
             to screening

          7. Patients with any other serious medical disease that may interfere with treatment by
             the investigational product

          8. Where there is psychiatric history that may compromise compliance with the protocol

          9. Patients with findings of autoimmune or inflammatory disease, whose abnormal results
             from an autoimmune response test have been deemed clinically significant by an
             investigator

         10. Patients deemed unsuitable to participate in the present study by an investigator due
             to comorbidities other than the above

         11. Patients who are unsuitable to participate in the present study due to the production
             period and nature of the investigational product